Premium
Bone marrow karyotype and prognosis in primary myelodysplastic syndromes
Author(s) -
Billström Rolf,
Thiede Torben,
Hansen Sören,
Heim Sverre,
Kristoffersson Ulf,
Mandahl Nils,
Mitelman Felix
Publication year - 1988
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1988.tb00207.x
Subject(s) - karyotype , myelodysplastic syndromes , bone marrow , monosomy , medicine , international prognostic scoring system , oncology , cytogenetics , pathology , chromosome 7 (human) , chromosome , biology , genetics , gene
Bone marrow karyotype, survival time, and the rate of progression to leukaemia were studied in 111 unselected patients with primary myelodysplastic syndromes. The 49 patients (44%) with clonal chromosome aberrations had survival time (median 29 months) similar to that found in the 62 patients with normal bone marrow karyotype (24 months, p > 0.10). The presence of multiple (> 2) abnormalities (17 patients) was strongly associated with poor prognosis, with a median survival of only 7 months (p < 0.001). Prognostic information could be attributed to 2 specific abnormalities, del(5q) and ‐7: Presence of del(5q) as the sole anomaly was associated with long survival (36+ months), whereas monosomy 7 was a bad prognostic sign (6 months). The risk for leukaemia development correlated neither with the number of chromosome abnormalities nor with any particular anomaly. Our findings demonstrate the prognostic importance of quantifying the complexity of bone marrow chromosome changes. They also emphasize that different specific abnormalities convey widely different prognostic information in primary myelodysplastic syndromes.